Area of research
Statistical and Nonlinear Physics · Molecular Biology
Research interest
Research interests include Nonlinear Waves and Solitons, Nonlinear Photonic Systems, Fibroblast Growth Factor Research, and Advanced Fiber Laser Technologies.
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
DeepGate2: Functionality-Aware Circuit Representation Learning
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)
Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements
FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)